Sarcopenia, the loss of skeletal muscle mass and function, commonly complicates chronic obstructive pulmonary disease (COPD) and contributes to worse clinical outcomes. Alpha-1 antitrypsin deficiency (AATD), caused by pathogenic variants in SERPINA1, is the most common genetic cause of COPD. The impact of AATD genotypes, particularly the Z allele, on skeletal muscle mass and sarcopenia risk has not been fully characterized.
This study assessed whether carriage of the SERPINA1 Z allele (genotypes such as PIMZ, PISZ, PI*ZZ) associates with measures of muscle mass and with sarcopenia and mortality in a large population cohort.
The investigators performed a retrospective analysis of 487,207 participants from the UK Biobank with available SERPINA1 genotyping. Primary muscle-related outcomes included fat free mass index (FFMI) and appendicular skeletal muscle index (ASMI). A binary definition of sarcopenia was also used, though the abstract does not specify the exact threshold values applied.
Associations between AAT genotypes and muscle measures were evaluated using multivariable linear and logistic regression models. Models were adjusted for potential confounders: age, sex, smoking status, genetic principal components, lung function (FEV1% predicted), and liver fibrosis risk (FIB-4). The analysis examined genotype dose effects across PIMM (reference), PIMZ, PISZ, and PIZZ groups.
Mortality associations with the Z allele were estimated using adjusted regression models. The authors also conducted mediation analysis to quantify how much of the allele–mortality association could be explained by sarcopenia.
Compared with PI*MM individuals, carriers of the Z allele (PIMZ, PISZ, PI*ZZ) showed significantly lower FFMI and ASMI and had higher odds of meeting the study’s binary sarcopenia definition. These associations remained significant after adjustment for lung function and liver fibrosis risk, indicating effects independent of those organ systems.
A dose-dependent relationship was observed: the largest reductions in muscle mass and the highest odds of sarcopenia were present among PI*ZZ individuals. For FFMI-defined sarcopenia, PIZZ carriage was associated with an adjusted odds ratio of 2.02 (95% CI 1.16–3.32) compared with PIMM.
Each additional Z allele was associated with increased mortality risk; the adjusted odds ratio per additional Z allele was 1.09 (95% CI 1.02–1.16). Mediation analysis estimated that sarcopenia accounted for a modest proportion of the allele–mortality association, approximately 2.6%.
The abstract does not report absolute muscle mass values, the prevalence of sarcopenia in each genotype group, specific model coefficients beyond the reported ORs, or stratified analyses by age, sex, or COPD status. Those details would require review of the full manuscript or supplementary materials.
In this large UK Biobank cohort, the SERPINA1 Z allele was associated with reduced skeletal muscle mass and increased odds of sarcopenia in a dose-dependent manner, independent of measured lung and liver disease. The presence of the Z allele was also associated with a modestly increased risk of mortality, with sarcopenia mediating a small portion of that risk.
These findings expand the recognized phenotype of Alpha-1 antitrypsin deficiency to include skeletal muscle involvement and suggest skeletal muscle may represent a modifiable target for intervention in persons with Z-allele carriage.
The authors disclosed multiple funding sources and relationships. Financial support included grants from the National Institutes of Health and the Alpha-1 Foundation. Several authors reported consulting, advisory roles, royalties, research contracts, or honoraria with pharmaceutical and diagnostic companies; specific relationships are listed in the source article. The abstract states that other authors declared no known competing financial interests.
Ethical approval for the work was provided by the Cleveland Clinic IRB. The study used UK Biobank data under application number 61825. Access to the underlying UK Biobank data is available to approved researchers through the UK Biobank Research Analysis Platform. The abstract does not supply additional protocol details or the exact sarcopenia criteria used; those elements would be available in the full text or supplementary material.